A study to determine the change in serum periostin level over 12 weeks in adult patients following a severe exacerbation of asthma

Medical Research Institute of New Zealand0 个研究点目标入组 34 人开始时间: 2014年4月30日最近更新: 2020年1月13日

试验速览

暂无简介。

•Aged between 18 to 75 years
•Able to provide written informed consent
•Doctor diagnosis of asthma
•Exacerbation of asthma, defined as one or both of the following criteria:
•Use of systemic corticosteroids (tablets, suspension, or injection), or an increase from a stable maintenance dose, for at least 3 days. For consistency, courses of corticosteroids separated by 1 week or more should be treated as separate severe exacerbations.
•A hospitalization or Emergency Department visit because of asthma, requiring systemic corticosteroids. requiring admission to hospital
•Participants prescribed a dose of systemic corticosteroids for at least 3 days will be eligible for the study, though it is recognised they will not have taken systemic corticosteroids for 3 days at the point of enrolment. Participants will not be eligible if they have commenced systemic corticosteroids greater than 24 hours prior to enrolment.
•Participants who have increased from their stable maintenance dose of systemic corticosteroids will only be eligible if this dose increase is confirmed to be less than 24 hours prior to enrolment.

•Known Pregnancy
•Significant co morbidities (determined at investigator discretion)
•Hospital admission within last 3 months for condition other than asthma
•Surgery within last 3 months, determined at investigator discretion (this includes all major surgery requiring general anaesthetic, dental extractions and root canal procedures. This does not include minor procedures, including but not limited to mole or wart removal, dental fillings etc).
•Bone fracture within the last 3 month
•Any other safety concern at the investigator’s discretion

发起方